NEW YORK (GenomeWeb) – BASF announced it has reached a non-exclusive, worldwide licensing agreement with the Broad Institute for CRISPR/Cas9 genome editing in ag-bio and industrial applications.
"We are eager to see the new ways it will augment our research and improve multiple products for agriculture as well as numerous industrial applications," Peter Eckes, president of BASF bioscience research, said in a statement.
It's the Broad's second ag-bio licensing deal for CRISPR/Cas9, following the September 2016 agreement with Monsanto.